A Non-interventional Post-marketing Study, Evaluating Seizure Control and Tolerability of Vimpat as Adjunctive Therapy to One Baseline Antiepileptic Drug in Epilepsy Patients With Partial-onset Seizures With or Without Secondary Generalization in Daily Clinical Practice in Germany

Trial Profile

A Non-interventional Post-marketing Study, Evaluating Seizure Control and Tolerability of Vimpat as Adjunctive Therapy to One Baseline Antiepileptic Drug in Epilepsy Patients With Partial-onset Seizures With or Without Secondary Generalization in Daily Clinical Practice in Germany

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Lacosamide (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Acronyms VITOBA
  • Sponsors UCB
  • Most Recent Events

    • 03 Nov 2015 Results published in the Epilepsia
    • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 25 Apr 2015 Results of sub group analysis presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top